Concepts (172)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Perioperative Care | 3 | 2018 | 997 | 0.570 |
Why?
|
| Vasopressins | 1 | 2017 | 370 | 0.530 |
Why?
|
| Intubation, Intratracheal | 4 | 2018 | 1357 | 0.520 |
Why?
|
| Plasma | 1 | 2017 | 575 | 0.470 |
Why?
|
| Vasoconstrictor Agents | 1 | 2017 | 643 | 0.470 |
Why?
|
| Vasodilator Agents | 1 | 2017 | 976 | 0.440 |
Why?
|
| Erythrocyte Transfusion | 1 | 2017 | 565 | 0.420 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2017 | 1517 | 0.370 |
Why?
|
| Anesthesia | 2 | 2018 | 1548 | 0.310 |
Why?
|
| Quality Assurance, Health Care | 1 | 2018 | 2211 | 0.310 |
Why?
|
| Intraoperative Complications | 3 | 2007 | 1188 | 0.270 |
Why?
|
| Anesthetics | 2 | 2021 | 538 | 0.230 |
Why?
|
| Adrenergic beta-Antagonists | 2 | 2018 | 1239 | 0.210 |
Why?
|
| Awareness | 1 | 2007 | 639 | 0.210 |
Why?
|
| Blood Pressure | 2 | 2017 | 8541 | 0.210 |
Why?
|
| Anesthesia, General | 2 | 2007 | 1164 | 0.200 |
Why?
|
| Southeastern United States | 1 | 2018 | 95 | 0.160 |
Why?
|
| Nevirapine | 1 | 1998 | 267 | 0.150 |
Why?
|
| Hepatic Encephalopathy | 1 | 1998 | 139 | 0.150 |
Why?
|
| Duodenum | 1 | 2019 | 483 | 0.140 |
Why?
|
| Latex | 1 | 1996 | 52 | 0.140 |
Why?
|
| Laminectomy | 1 | 2017 | 232 | 0.140 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 2020 | 454 | 0.130 |
Why?
|
| Aneurysm, Ruptured | 1 | 2021 | 452 | 0.130 |
Why?
|
| Palpation | 1 | 1995 | 166 | 0.130 |
Why?
|
| Reverse Transcriptase Inhibitors | 1 | 1998 | 615 | 0.130 |
Why?
|
| Rectum | 1 | 2019 | 903 | 0.120 |
Why?
|
| Monitoring, Intraoperative | 2 | 2017 | 953 | 0.120 |
Why?
|
| Blood Pressure Determination | 1 | 2017 | 632 | 0.110 |
Why?
|
| Suicidal Ideation | 1 | 2022 | 1246 | 0.110 |
Why?
|
| Child Behavior Disorders | 1 | 1998 | 807 | 0.110 |
Why?
|
| Community Health Services | 1 | 2018 | 650 | 0.110 |
Why?
|
| Intracranial Aneurysm | 1 | 2021 | 1197 | 0.100 |
Why?
|
| Suicide | 1 | 2022 | 1475 | 0.100 |
Why?
|
| Cardiovascular System | 1 | 2018 | 827 | 0.100 |
Why?
|
| Mortality | 2 | 2018 | 2857 | 0.090 |
Why?
|
| Parent-Child Relations | 1 | 1994 | 747 | 0.090 |
Why?
|
| Spinal Fusion | 1 | 2017 | 1234 | 0.080 |
Why?
|
| Quality Indicators, Health Care | 1 | 2018 | 1831 | 0.080 |
Why?
|
| Hypersensitivity | 1 | 1996 | 1093 | 0.070 |
Why?
|
| Medication Adherence | 1 | 2018 | 2055 | 0.070 |
Why?
|
| Child Development | 1 | 1998 | 2222 | 0.070 |
Why?
|
| Anti-HIV Agents | 2 | 1998 | 4250 | 0.070 |
Why?
|
| Aortic Valve Stenosis | 1 | 1998 | 1941 | 0.070 |
Why?
|
| Parents | 2 | 2022 | 3387 | 0.070 |
Why?
|
| Incidence | 3 | 2018 | 20928 | 0.060 |
Why?
|
| HIV Infections | 4 | 2019 | 16678 | 0.060 |
Why?
|
| Female | 17 | 2019 | 379592 | 0.060 |
Why?
|
| Databases, Factual | 1 | 2018 | 7716 | 0.060 |
Why?
|
| Retrospective Studies | 5 | 2020 | 77098 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 1998 | 4229 | 0.050 |
Why?
|
| Aged | 7 | 2018 | 162944 | 0.050 |
Why?
|
| Longitudinal Studies | 1 | 2018 | 13921 | 0.050 |
Why?
|
| Male | 16 | 2019 | 349538 | 0.050 |
Why?
|
| Humans | 21 | 2022 | 742088 | 0.050 |
Why?
|
| Hospitalization | 1 | 2020 | 10232 | 0.050 |
Why?
|
| Mental Recall | 1 | 2007 | 1205 | 0.050 |
Why?
|
| Prevalence | 1 | 2017 | 15194 | 0.050 |
Why?
|
| CD4-CD8 Ratio | 1 | 2019 | 112 | 0.050 |
Why?
|
| Middle Aged | 11 | 2018 | 213127 | 0.040 |
Why?
|
| Postoperative Complications | 2 | 2020 | 15244 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2018 | 53187 | 0.040 |
Why?
|
| Mid-Atlantic Region | 1 | 2018 | 23 | 0.040 |
Why?
|
| Thiopental | 1 | 1998 | 59 | 0.040 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 1998 | 45 | 0.040 |
Why?
|
| Succinylcholine | 1 | 1998 | 66 | 0.040 |
Why?
|
| Evoked Potentials, Somatosensory | 1 | 1999 | 247 | 0.040 |
Why?
|
| Escape Reaction | 1 | 1998 | 54 | 0.040 |
Why?
|
| Infant | 7 | 2022 | 35070 | 0.040 |
Why?
|
| Defense Mechanisms | 1 | 1998 | 179 | 0.040 |
Why?
|
| Aortic Coarctation | 1 | 1999 | 281 | 0.040 |
Why?
|
| Child, Preschool | 7 | 2022 | 40955 | 0.040 |
Why?
|
| Blood | 1 | 2019 | 598 | 0.040 |
Why?
|
| Didanosine | 1 | 1996 | 153 | 0.040 |
Why?
|
| Aged, 80 and over | 3 | 2018 | 57683 | 0.040 |
Why?
|
| Time | 1 | 2018 | 530 | 0.030 |
Why?
|
| Dissociative Disorders | 1 | 1998 | 231 | 0.030 |
Why?
|
| Cardiac Output | 1 | 1998 | 853 | 0.030 |
Why?
|
| Pregnancy | 1 | 2017 | 29087 | 0.030 |
Why?
|
| Fentanyl | 1 | 1998 | 410 | 0.030 |
Why?
|
| Bronchoscopes | 1 | 1995 | 62 | 0.030 |
Why?
|
| Immunophenotyping | 1 | 2019 | 1866 | 0.030 |
Why?
|
| Isoflurane | 1 | 1998 | 381 | 0.030 |
Why?
|
| Anesthetics, Intravenous | 1 | 1998 | 417 | 0.030 |
Why?
|
| Ribavirin | 1 | 1996 | 395 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 62966 | 0.030 |
Why?
|
| Sternum | 1 | 1995 | 175 | 0.030 |
Why?
|
| Adolescent | 8 | 2022 | 85649 | 0.030 |
Why?
|
| Spinal Dysraphism | 1 | 1996 | 160 | 0.030 |
Why?
|
| Educational Status | 1 | 2022 | 2533 | 0.030 |
Why?
|
| Adult | 10 | 2020 | 213712 | 0.030 |
Why?
|
| Risk Factors | 2 | 2017 | 72145 | 0.030 |
Why?
|
| Anesthetics, Inhalation | 1 | 1998 | 571 | 0.030 |
Why?
|
| Patient Admission | 1 | 2020 | 1380 | 0.030 |
Why?
|
| Life Change Events | 1 | 1998 | 937 | 0.030 |
Why?
|
| Patient Care Planning | 1 | 1998 | 921 | 0.030 |
Why?
|
| Sex Distribution | 1 | 1998 | 2295 | 0.030 |
Why?
|
| Cardiovascular Diseases | 1 | 2018 | 15108 | 0.030 |
Why?
|
| Child | 8 | 2022 | 77478 | 0.030 |
Why?
|
| Surface Properties | 1 | 1995 | 1182 | 0.030 |
Why?
|
| Infant, Newborn | 4 | 2022 | 25575 | 0.030 |
Why?
|
| Pressure | 1 | 1995 | 1203 | 0.030 |
Why?
|
| Arousal | 1 | 1998 | 1165 | 0.030 |
Why?
|
| Cerebral Palsy | 1 | 1996 | 459 | 0.020 |
Why?
|
| Acyclovir | 1 | 1992 | 272 | 0.020 |
Why?
|
| Bronchi | 1 | 1995 | 840 | 0.020 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2019 | 1872 | 0.020 |
Why?
|
| Vidarabine | 1 | 1992 | 345 | 0.020 |
Why?
|
| Poverty | 1 | 2022 | 2646 | 0.020 |
Why?
|
| Hypotension | 1 | 1996 | 880 | 0.020 |
Why?
|
| Urinary Tract Infections | 1 | 1996 | 786 | 0.020 |
Why?
|
| Herpes Zoster | 1 | 1992 | 264 | 0.020 |
Why?
|
| Linear Models | 1 | 2019 | 5948 | 0.020 |
Why?
|
| Anaphylaxis | 1 | 1996 | 746 | 0.020 |
Why?
|
| Lymphocyte Activation | 1 | 2019 | 5519 | 0.020 |
Why?
|
| Intestinal Mucosa | 1 | 2019 | 3038 | 0.020 |
Why?
|
| Mast Cells | 1 | 1996 | 1544 | 0.020 |
Why?
|
| Biopsy | 1 | 2019 | 6756 | 0.020 |
Why?
|
| Adaptation, Psychological | 1 | 1998 | 2575 | 0.020 |
Why?
|
| Liver Transplantation | 1 | 1998 | 2117 | 0.020 |
Why?
|
| Equipment Design | 1 | 1995 | 3582 | 0.020 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2019 | 4379 | 0.020 |
Why?
|
| Heart Rate | 1 | 1998 | 4091 | 0.020 |
Why?
|
| Hospitals | 1 | 2020 | 3937 | 0.020 |
Why?
|
| Homeostasis | 1 | 1998 | 3335 | 0.020 |
Why?
|
| Immunocompromised Host | 1 | 1992 | 847 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 1998 | 3656 | 0.020 |
Why?
|
| Heart | 1 | 2018 | 4462 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 1996 | 2978 | 0.010 |
Why?
|
| Social Support | 1 | 1994 | 2117 | 0.010 |
Why?
|
| Meningitis, Viral | 1 | 1983 | 50 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 1998 | 7901 | 0.010 |
Why?
|
| Emotions | 1 | 1994 | 2657 | 0.010 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 1994 | 3915 | 0.010 |
Why?
|
| HIV-1 | 1 | 1996 | 6934 | 0.010 |
Why?
|
| Spinal Cord Ischemia | 1 | 1999 | 93 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2020 | 40450 | 0.010 |
Why?
|
| Cytomegalovirus | 1 | 1982 | 730 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 1995 | 19862 | 0.010 |
Why?
|
| Giant Cells | 1 | 1996 | 187 | 0.010 |
Why?
|
| Viremia | 1 | 1996 | 735 | 0.010 |
Why?
|
| Neuritis | 1 | 1992 | 37 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1996 | 1458 | 0.010 |
Why?
|
| Skin Diseases, Infectious | 1 | 1992 | 74 | 0.010 |
Why?
|
| Meningoencephalitis | 1 | 1992 | 78 | 0.010 |
Why?
|
| Hepatitis, Viral, Human | 1 | 1992 | 138 | 0.010 |
Why?
|
| Brain | 1 | 1998 | 26343 | 0.010 |
Why?
|
| Antibodies, Viral | 1 | 1982 | 3164 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 1996 | 2557 | 0.010 |
Why?
|
| RNA, Viral | 1 | 1996 | 2899 | 0.000 |
Why?
|
| Infusions, Intravenous | 1 | 1992 | 2271 | 0.000 |
Why?
|
| Drug Therapy, Combination | 1 | 1996 | 6483 | 0.000 |
Why?
|
| Echovirus 9 | 1 | 1983 | 1 | 0.000 |
Why?
|
| Echovirus Infections | 1 | 1983 | 7 | 0.000 |
Why?
|
| Enterovirus B, Human | 1 | 1983 | 52 | 0.000 |
Why?
|
| Coxsackievirus Infections | 1 | 1983 | 44 | 0.000 |
Why?
|
| Malta | 1 | 1982 | 6 | 0.000 |
Why?
|
| Education, Special | 1 | 1983 | 87 | 0.000 |
Why?
|
| Adenovirus Infections, Human | 1 | 1983 | 71 | 0.000 |
Why?
|
| Enterovirus | 1 | 1983 | 64 | 0.000 |
Why?
|
| Brain Damage, Chronic | 1 | 1983 | 265 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1996 | 6540 | 0.000 |
Why?
|
| Herpes Simplex | 1 | 1983 | 466 | 0.000 |
Why?
|
| Cost-Benefit Analysis | 1 | 1992 | 5385 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1992 | 12017 | 0.000 |
Why?
|
| Intelligence | 1 | 1983 | 920 | 0.000 |
Why?
|
| Pneumonia, Viral | 1 | 1992 | 3236 | 0.000 |
Why?
|
| Disabled Persons | 1 | 1983 | 1209 | 0.000 |
Why?
|
| Mothers | 1 | 1982 | 2163 | 0.000 |
Why?
|
| Sex Factors | 1 | 1982 | 10392 | 0.000 |
Why?
|
| Age Factors | 1 | 1982 | 18355 | 0.000 |
Why?
|
| Follow-Up Studies | 1 | 1983 | 39004 | 0.000 |
Why?
|
Concepts
(172)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(5)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_